

## REVIEWER'S REPORT

Manuscript No.: IJAR-58909

**Title: Comparative Evaluation of the Antimicrobial Efficacy of 3% Nisin-Modified Endoflas F.S and Conventional Endoflas F.S Against Escherichia coli: An In Vitro Study.**

### Recommendation:

Accept as it is ☐☐☐☐..

Accept after minor revision ☐☐☒☐

Accept after major revision ☐☐☐☐

Do not accept (*Reasons below*) ☐☐☐

| Rating         | Excel. | Good | Fair | Poor |
|----------------|--------|------|------|------|
| Originality    |        | √    |      |      |
| Techn. Quality |        | √    |      |      |
| Clarity        |        | √    |      |      |
| Significance   |        | √    |      |      |

Reviewer ID: JP085

### Reviewer's Comment for Publication.

This article compares normal Endoflas F.S. with Endoflas F.S. containing 3% Nisin. The study tested their antibacterial activity against E. coli in the laboratory. Two tests were used. The Nisin-added Endoflas showed better antibacterial activity than normal Endoflas.

### Strength:

1. The topic is useful and relevant.
2. The aim of the study is clear.
3. Two antibacterial tests were used.
4. The preparation of Nisin-modified Endoflas is explained.
5. Results are given in tables and graphs.
6. The study found better activity with Nisin-modified Endoflas.

### Weakness:

1. Only E. coli was tested.
2. The number of samples or repeated tests is not clearly mentioned.
3. Statistical analysis and p-values are not given.
4. The difference in inhibition zone is small: 2.1 cm vs 2.3 cm.
5. The study was done only in the laboratory, not in patients.
6. Biofilm testing was not done.
7. Safety and cell compatibility of the modified material were not tested.
8. Physical properties of the modified Endoflas were not studied.
9. Some grammar, spelling and formatting errors are present.

### Overall assessment:

# International Journal of Advanced Research

**Publisher's Name: Jana Publication and Research LLP**

*www.journalijar.com*

---

## **REVIEWER'S REPORT**

The article has a good research idea and shows that adding 3% Nisin may improve the antibacterial activity of Endoflas F.S. However, more information about the experimental samples and statistical analysis is needed. Further studies with different bacteria and clinical conditions are also required.

**Recommendation:** Manuscript accepted for publication after minor revision.